Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4085933 | 0.88 | CXCR2 (0.53) | CXCR2 | |
| SCHEMBL5261812 | 0.88 | CXCR2 (0.73) | CXCR2 | |
| SCHEMBL2037174 | 0.88 | CXCR2 (0.73) | CXCR2 | |
| SCHEMBL4076772 | 0.87 | CXCR2 (0.58) | CXCR2 | |
| SCHEMBL4077242 | 0.81 | CXCR2 (0.58) | CXCR2 | |
| SCHEMBL4080580 | 0.80 | CXCR2 (0.73) | CXCR2 | |
| SCHEMBL14645653 | 0.79 | HTT (0.65) | HTT | |
| SCHEMBL4077480 | 0.79 | CXCR2 (0.49) | CXCR2HTT | |
| SCHEMBL13067223 | 0.75 | HTT (0.79) | HTT | |
| SCHEMBL489949 | 0.75 | CXCR2 (0.71) | CXCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7482355-B2 | Asthma, antiallergens; rheumatoid arthritis and atherosclerosis; 2-(Benzylthio)-6-{[(1R)-2-hydroxy-1-methylethyl]amino}-4-pyrimidinol | ASTRAZENECA AB (SE) | 2009-01-27 | — | — | US | disclosed |
| EP-1539713-B1 | PYRIMIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | ASTRAZENECA AB (SE) | 2007-12-19 | — | — | EP | disclosed |
| US-20060004030-A1 | Pyrimidine derivatives as modulators of chemokine receptor activity | ASTRAZENECA AB (SE) | 2006-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004030-A1 | Pyrimidine derivatives as modulators of chemokine receptor activity | CXCR2, CXCR1, ACKR3 | CXCR2 1/4885HTT 4620/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.